Source: International Journal of Atherosclerosis. Unidade: FM
Subjects: ANTIBIÓTICOS, ESTUDO DE CASO, CHLAMYDIA (PATOGENICIDADE), CONTENEDORES (EFEITOS ADVERSOS), SEGUIMENTOS, CORONARIOPATIA (PREVENÇÃO E CONTROLE)
ABNT
IKEOKA, D. T. et al. Anti-Chlamydia azithromycin therapy for the prevention of coronary renarrowing after stenting (ACTOR trial): a randomized double-blinded, controlled trial. International Journal of Atherosclerosis, v. 2, n. 1, p. 63-67, 2006Tradução . . Acesso em: 17 ago. 2024.APA
Ikeoka, D. T., Lemos, P. A., Vieira, C. Z., Strabelli, T. V., Silva, E. E. R. da, Perin, M. A., et al. (2006). Anti-Chlamydia azithromycin therapy for the prevention of coronary renarrowing after stenting (ACTOR trial): a randomized double-blinded, controlled trial. International Journal of Atherosclerosis, 2( 1), 63-67.NLM
Ikeoka DT, Lemos PA, Vieira CZ, Strabelli TV, Silva EER da, Perin MA, Tiran B, Tiran A, Caramelli B. Anti-Chlamydia azithromycin therapy for the prevention of coronary renarrowing after stenting (ACTOR trial): a randomized double-blinded, controlled trial. International Journal of Atherosclerosis. 2006 ; 2( 1): 63-67.[citado 2024 ago. 17 ]Vancouver
Ikeoka DT, Lemos PA, Vieira CZ, Strabelli TV, Silva EER da, Perin MA, Tiran B, Tiran A, Caramelli B. Anti-Chlamydia azithromycin therapy for the prevention of coronary renarrowing after stenting (ACTOR trial): a randomized double-blinded, controlled trial. International Journal of Atherosclerosis. 2006 ; 2( 1): 63-67.[citado 2024 ago. 17 ]